Trial Profile

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary) ; Busulfan; Cyclophosphamide; Fludarabine; Melphalan; Methotrexate; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
Indications Graft-versus-host disease; Myelofibrosis
Focus Therapeutic Use

Most Recent Events

26 Feb 2025 Planned number of patients changed from 45 to 60.
29 Apr 2024 Treatments section is updated to add the procedures of CT scan, Echocardiography, Bone Marrow Aspiration and Biopsy, ultrasound and MRI
10 Jan 2023 Planned End Date changed from 31 Dec 2028 to 31 Dec 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com